| answer text |
<p>The Government is committed to ensuring the UK remains a global leader in life
sciences and continues to collaborate with European and other countries on scientific
research. At the end of the UK transition period, clinical trials will continue to
be approved at a national level, working to international standards as they are now.
The Medicines and Healthcare Products Regulatory Agency (MHRA) along with partners
in the UK healthcare system, has taken steps to ensure that all trials, including
multinational trials, can continue. The UK is collaborating extensively with international
partners in the research effort against COVID-19 and we will continue to do so after
the end of the UK transition period.</p><p>The UK’s approach to the future relationship
negotiations sets out our ambition to reach an agreement that would facilitate trade
in medicinal products. However, any responsible Government has a duty to prepare for
all scenarios and have robust contingency plans in place. We continue to hold stockpiles
to cope with a range of scenarios.</p><p>We are doing everything we can to ensure
our health and social care staff have the equipment they need to tackle Covid-19 virus.
Sourcing sufficient PPE is an international challenge and we are working with many
international partners, including the EU. In terms of ventilators, as a result of
the Ventilator Challenge the NHS has significantly increased supply.</p><p> </p>
|
|
